WeightWatchers' Stock Skyrockets on Acquisition Deal and Obesity-Drug Related Optimism

WW International's stock surged 59% after Goldman Sachs analyst Jason English upgraded his rating on the stock to buy from neutral following the company's acquisition of telehealth provider Sequence. English also raised his price target on WW to $13 from $3.80, implying that shares could surge 216% from their close on Monday. The acquisition will help WW access the growing market for new obesity drugs, which should boost its earnings per share and lead the stock higher.